hVIVO plc (AIM: HVO), a specialist contract research organisation (CRO) in infectious disease testing, has announced positive topline results from a Phase 2a Respiratory Syncytial Virus (RSV) human challenge trial for Enanta Pharmaceuticals' antiviral candidate EDP-323. This trial involved 142 healthy adult volunteers and demonstrated significant antiviral efficacy.
Participants were divided into three groups - high dose, low dose and placebo. Results indicated that EDP-323 achieved an 85-87% reduction in viral load as measured by qRT-PCR, a 97-98% reduction in infectious viral load via viral culture, and a 66-78% decrease in total clinical symptoms score, all with p-values less than 0.0001.
The successful outcomes underscore the value of human challenge trials in expediting efficacy data and mitigating risks in later-stage clinical development. With over 30 years of experience, hVIVO supports crucial research across various respiratory viruses, including RSV and COVID-19.
EDP-323, an oral antiviral, has received U.S. Food and Drug Administration (FDA) Fast Track designation.
Enanta's first RSV candidate, Zelicapavir (EDP-938), has also shown promising results in prior trials.
hVIVO operates from its state-of-the-art facilities in Canary Wharf, London, the world's largest commercial human challenge trial unit, equipped with advanced virology and immunology laboratories. The Group offers a comprehensive suite of early clinical development services, maintaining partnerships with four of the top ten global biopharma companies.
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
hVIVO reports positive results from RSV antiviral human challenge trial
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Liquidia and Pharmosa expand collaboration for inhaled treprostinil
Alvotech launches confirmatory study for Entyvio biosimilar
Merck's KEYTRUDA receives new approvals in Japan for lung and urothelial cancers
Innate Pharma receives FDA clearance of IND for IPH4502, a Nectin-4 targeting ADC for solid tumours
Intas Pharmaceuticals reports positive opinion for HETRONIFLY in Europe
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024